HealthQuill Pharma
Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.
Drugs Health Pharma

Novo Nordisk, Septerna in $2.2b deal to develop oral molecules

HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.

Read More
GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.
Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.

Read More
The Food and Drug Administration has cleared the first at-home cervical cancer screening test in the US, according to a statement from Teal Health, its maker.
Health Medical Pharma

US approves first at-home cervical cancer screening from Teal Health

HQ Team May 12, 2025: The Food and Drug Administration has cleared the first at-home cervical cancer screening test in the US, according.

Read More
At least 78% of the world’s nurses are concentrated in countries representing 49% of the population, according to a global nursing report published by the World Health Organization and the International Council of Nurses.
Health Medical Pharma

Global health goals face risks due to inequities in nursing profession: WHO

HQ Team May 12, 2025: At least 78% of the world’s nurses are concentrated in countries representing 49% of the population, according to.

Read More
Merck Animal Health will invest $895 million in its US facility to develop novel parasiticides and therapeutics, and expand, filling and freeze dryer capacity, according to a company statement.
Drugs Health Pharma

Merck Animal Health to invest $895 million to expand facility in US

HQ Team May 8, 2025: Merck Animal Health will invest $895 million in its US facility to develop novel parasiticides and therapeutics, and.

Read More
Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the National Institutes of Health to advance its Alzheimer’s vaccine to human trials.
Drugs Health Pharma

Nuravax’s Alzheimer’s vaccine gets $3m grant to enter human trials

HQ Team May 5, 2025: Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the.

Read More
The Global Virus Network warned of an avian influenza currently circulating in the US, spreading to humans and urged enhanced surveillance, biosecurity measures and preparations for a potential human-to-human transmission.
Drugs Health Pharma

Global virologists see potential for an H5N1 pandemic, urge rapid steps

HQ Team May 5, 2025: The Global Virus Network warned of an avian influenza currently circulating in the US, spreading to humans and.

Read More
UK scientists at biotech company Stablepharma have developed a tetanus-diphtheria vaccine that is completely stable at room temperature and does not need to be refrigerated or frozen.
Drugs Health Pharma

UK company starts trial on first ‘fridge-free’ tetanus-diphtheria vaccine

HQ Team May 1, 2025: UK scientists at biotech company Stablepharma Ltd. have developed a tetanus-diphtheria vaccine that is completely stable at room.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment. 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a.

Read More